Best mRNA / LNP CDMOs in South Korea
· updated as new inspection, certificate, and trial data enters the platform
3
CDMOs tracked
2
Fully scored
1
With FDA records
2
FDA inspections
4
EMA/MHRA GMP certs
mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.
Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 0 NAI (no action), 1 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (2), Czechia (2), Germany (1), Ireland (1).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
SP
ST Pharm
Seoul, South Korea
|
72.8 | 88.1 | 2 insp · 4 GMP | — | 0 programs |
| 2 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
|
61.5 | — | — | Available | 0 programs |
| — |
CdmoGen Co., Ltd.
Cheongju, South Korea
|
Profiled | — | — | — | 0 programs |
What to evaluate in a mRNA / LNP CDMO
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
What has driven South Korea's rise as a biologics manufacturing hub?
South Korea's biologics CDMO growth (2015-present) has been driven by three factors: (1) Samsung Biologics' massive Songdo capacity build (Plants 1-5 total >600,000L mammalian cell culture, one of the largest single-city concentrations of biologics capacity globally); (2) Celltrion's biosimilar-driven commercial capacity, exported globally; (3) national policy focus on biopharmaceutical export as a strategic industry. Korean CDMOs supplying US and EU markets typically hold MFDS + FDA + EMA certifications concurrently — the Signal Score's Quality Compliance pillar captures all three. For biologics programs specifically, South Korea offers commercial-scale capacity availability that is genuinely scarce in the US and EU.
How do Samsung Biologics and Celltrion compare on CDMO offerings?
Samsung Biologics operates primarily as a contract manufacturer (CDMO) with dedicated commercial biologics capacity at Songdo; Celltrion combines internal biosimilar development with CDMO services, with significant capacity dedicated to their own commercial products. For pure CDMO engagements, Samsung Biologics is typically the more scale-available option; for programs where biosimilar development experience is a plus, Celltrion's integrated model can add value. Both hold FDA and EMA certifications. Cross-check with the biologics CDMO ranking for the broader Korean biologics landscape and individual profile pages for facility-level detail.
South Korean CDMOs supplying US and EU markets — regulatory considerations
South Korean CDMOs supplying US and EU markets need active FDA and EMA GMP certifications on the specific facility. Both regulators have inspection experience with major Korean biologics sites, and inspection outcomes have generally been favorable. For programs supplying UK specifically, post-Brexit MHRA acceptance of MFDS + EMA-recognized inspections has continued under transitional arrangements — sponsors should confirm current MHRA policy at RFP stage. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Korean CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
mRNA / LNP CDMOs — Frequently Asked Questions
Who are the top mRNA / LNP CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked mRNA / LNP CDMOs include ST Pharm, Samsung Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many mRNA / LNP CDMOs have FDA inspection records?
CDMO Signal tracks 1 mRNA / LNP CDMO with FDA inspection records and 4 EMA/MHRA GMP certificates across the group.
What should I look for in an mRNA / LNP CDMO?
Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.
Do mRNA CDMOs also make the LNP and plasmid?
Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.
Related modalities